Trial Profile

A first-in-human, randomized, placebo-controlled, dose escalation Phase 1/2 clinical trial of AT-001 in patients with Type 2 Diabetes

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Caficrestat (Primary)
Indications Diabetic cardiomyopathy; Heart failure; Myocardial infarction; Peripheral nervous system diseases
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept

Most Recent Events

16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
07 Jun 2019 Results published in the Applied Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com